// Index Comparison
ACCE Defense & Aerospace vs ACCE Biotech Catalysts
Head-to-head: performance, risk profile, and constituent overlap between two ACCE indices.
US
ACCE Defense & Aerospace →
Defense contractors and tier-1 suppliers with >40% defense revenue exposure. Focuses on prime contractors, subsystem suppliers, and munitions companies benefiting from multi-year budget cycles and replenishment demand.
US
ACCE Biotech Catalysts →
Binary catalyst pipeline — FDA approvals, late-stage trial readouts, and M&A targets. High conviction names with visible catalysts.
ACCE Defense & Aerospace — risk
Volatility 30d+22.3%
Volatility 90d+25.7%
Sharpe 90d0.23
Max drawdown-17.4%
Beta vs ITA0.47
ACCE Biotech Catalysts — risk
Volatility 30d+21.6%
Volatility 90d+25.2%
Sharpe 90d-1.05
Max drawdown-13.4%
Beta vs SPY0.91
Constituent overlap
0 stocks held by both indices (out of 7 and 6)
Top sectors — ACCE Defense & Aerospace
Industrials100.0%
Top sectors — ACCE Biotech Catalysts
Healthcare100.0%
ACCE Verdict
**Defense & Aerospace has outperformed Biotech Catalysts by 970 basis points since inception**, posting a 2.1% return versus biotech's -7.6% loss against a 4.74% benchmark.
Risk profiles tell different stories: both indices carry similar volatility around 25%, but Defense & Aerospace delivers a positive 0.23 Sharpe ratio while Biotech Catalysts sits deeply negative at -1.05, despite biotech's shallower maximum drawdown of -13.4% versus defense's -17.4%.
These indices share virtually nothing beyond high volatility — defense operates on predictable multi-year budget cycles with a defensive 0.47 beta, while biotech swings on binary FDA outcomes with near-market beta of 0.91.
**Defense & Aerospace suits investors seeking thematic exposure with lower market correlation and steady government demand drivers.** The 0.47 beta provides genuine portfolio diversification while capturing defense spending tailwinds. **Biotech Catalysts appeals to aggressive growth investors comfortable with binary outcomes and willing to stomach negative carry for potential catalyst-driven spikes.** The brutal -1.05 Sharpe ratio makes biotech a pure speculation play, while defense offers a more measured risk-reward profile for thematic allocation.